M LV5 Pill - white oval
Pill with imprint M LV5 is White, Oval and has been identified as Levetiracetam Extended Release 500 mg. It is supplied by Mylan Pharmaceuticals Inc.
Levetiracetam is used in the treatment of Seizures; Epilepsy and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy. Levetiracetam 500 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for M LV5

Levetiracetam Extended Release
- Imprint
- M LV5
- Strength
- 500 mg
- Color
- White
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Pyrrolidine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Mylan Pharmaceuticals Inc.
- Inactive Ingredients
-
silicon dioxide,
ethylcellulose,
hypromelloses,
lactose monohydrate,
magnesium stearate,
polydextrose,
polyethylene glycol,
titanium dioxide,
triacetin
Note: Inactive ingredients may vary.
Labelers / Repackagers
NDC Code | Labeler / Repackager |
---|---|
00378-6300 (Discontinued) | Mylan Pharmaceuticals Inc. |
51079-0127 (Discontinued) | UDL Laboratories Inc. |
More about levetiracetam
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (429)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: pyrrolidine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Levetiracetam oral/injection drug information
- Levetiracetam Extended-Release Tablets
- Levetiracetam Injection
- Levetiracetam Tablets
- Levetiracetam Oral Solution
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Professional resources
- Levetiracetam monograph
- Levetiracetam (FDA)
- Levetiracetam Extended Release Tablets (FDA)
- Levetiracetam Injection (FDA)
- Levetiracetam Injection, Concentrate (FDA)
- Levetiracetam Solution (FDA)
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.